Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs.
Alcock, L.J., Chang, Y., Jarusiewicz, J.A., Actis, M., Nithianantham, S., Mayasundari, A., Min, J., Maxwell, D., Hunt, J., Smart, B., Yang, J.J., Nishiguchi, G., Fischer, M., Mullighan, C.G., Rankovic, Z.(2022) ACS Med Chem Lett 13: 475-482
- PubMed: 35300081 
- DOI: https://doi.org/10.1021/acsmedchemlett.1c00650
- Primary Citation of Related Structures:  
7SHH - PubMed Abstract: 
Aberrant activation of the JAK-STAT signaling pathway has been implicated in the pathogenesis of a range of hematological malignancies and autoimmune disorders. Here we describe the design, synthesis, and characterization of JAK2/3 PROTACs utilizing a phenyl glutarimide (PG) ligand as the cereblon (CRBN) recruiter. SJ10542 displayed high selectivity over GSPT1 and other members of the JAK family and potency in patient-derived ALL cells containing both JAK2 fusions and CRLF2 rearrangements.
Organizational Affiliation: 
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.